ArgentinaTuberculosis profile
Population  2014 43 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.61 (0.58–0.63) 1.4 (1.4–1.5)
Mortality (HIV+TB only) 0.058 (0.023–0.11) 0.13 (0.05–0.25)
Prevalence  (includes HIV+TB) 13 (5.4–23) 30 (13–53)
Incidence  (includes HIV+TB) 10 (9.1–12) 24 (21–27)
Incidence (HIV+TB only) 0.74 (0.58–0.92) 1.7 (1.3–2.1)
         
Case detection, all forms (%) 89 (78–100)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.2–3.6) 15 (9.8–23)
MDR-TB cases among notified pulmonary
TB cases
160 (92–270) 200 (120–290)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 5 249   319
Pulmonary, clinically diagnosed 2 218   107
Extrapulmonary 1 255   47
       
Total new and relapse 9 195    
Previously treated, excluding relapses 843    
Total cases notified 10 038    
Among 9 195 new and relapse cases:
845 (9%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 894 (36%) 546 (41%) 2 940
Laboratory-confirmed RR-/MDR-TB cases     114
Patients started on MDR-TB treatment ***     78
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 580 (16)
HIV-positive TB patients 447 (28)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (51) 8 474
Previously treated cases, excluding relapse, registered in 2013 (40) 782
HIV-positive TB cases, all types, registered in 2013 (32) 554
RR-/MDR-TB cases started on second-line treatment in 2012 (34) 89
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.6
Culture (per 5 million population) 14.5
Drug susceptibility testing (per 5 million population) 2.0
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 4.3
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-26 Data: www.who.int/tb/data